A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo­Controlled Trial to Evaluate the Efficacy and the Safety of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

Project: Research

Project Details

StatusActive
Effective start/end date25/03/2124/03/26

Keywords

  • phase 3 study
  • treatment efficacy
  • treatment safety
  • Immune Thrombocytopenia